On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

For those that may not have the opportunity to be part of a clinical trial, Burke proceeds with a step-by-step process. Burke emphasizes that the first practical step is to educate oneself on the ...

Panelists discuss second-line treatment options and emerging approaches for HER2-mutated non–-small cell lung cancer (NSCLC), highlighting novel therapies and clinical strategies.

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer ...

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for ...

Bernd Kasper, MD, PhD, provides an overview of the phase 3 DeFi trial of nirogacestat for the treatment of patients with progressing desmoid tumors.

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...